The introduction of the fusion inhibitors in the HAART-regimens

H. Hasson, A. Castagna, M. Clementi, S. Menzo, A. Danise, A. Lazzarin

Research output: Contribution to journalArticle

Abstract

Interference with HIV entry into target cells provides a novel approach to the treatment of HIV infection. The inhibition of virus fusion with the co-receptor substrate seems the most specific and potentially best way to interfere with HIV infection and replication. The efficacy of the first compound available (enfuvirtide) is evident after the pre-registrative phase II and III studies showing also that the presence of anti gp 41 antibodies in the plasma of the treated patients does not interfere with drug activity. In the failing enfuvirtide treated patients resistant virus was detected in 7/7 after > one year of treatment with genotypic mutations in the HR env domain, however no interclass cross resistance was evidenced. Mutants selected in vivo demonstrated a slight reduction of replication capacity.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalNew Microbiologica
Volume27
Issue number2 SUPPL. 1
Publication statusPublished - 2004

Keywords

  • Enfuvirtide
  • Fusion inhibitors
  • HAART
  • HIV resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Fingerprint Dive into the research topics of 'The introduction of the fusion inhibitors in the HAART-regimens'. Together they form a unique fingerprint.

  • Cite this

    Hasson, H., Castagna, A., Clementi, M., Menzo, S., Danise, A., & Lazzarin, A. (2004). The introduction of the fusion inhibitors in the HAART-regimens. New Microbiologica, 27(2 SUPPL. 1), 11-16.